Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a

Hye-Youn Kim1, Young-Mi Kim2 & Suntaek Hong1,2

Colorectal cancer (CRC) is the third most common cancer, and is associated with a high percentage of cancer-related death globally. Furthermore, the success rate of therapeutic treatment for CRC patients mainly depends on the status of metastasis. Therefore, novel drugs or therapeutic techniques should be discovered for the treatment of metastatic CRC. In this study, we selected Astaxanthin (AXT), one of the most common carotenoids, as a novel metastasis inhibitor through high-throughput drug screening based on invadopodia staining, and confirmed the anti-migratory and anti-invasive activity of AXT. We demonstrated that AXT increases miR-29a-3p and miR-200a expression, and thereby suppresses the expression of MMP2 and ZEB1, respectively. As a result, AXT represses the epithelial-mesenchymal transition (EMT) of CRC cells. Through the mechanistic study, we identified that AXT shows anti-metastatic activity through the transcriptional repression of MYC transcription factor. Finally, we also confirmed that AXT suppresses the in vivo metastatic capacity of colon cancer cell using mouse model. Collectively, we uncovered the novel function of AXT in the inhibition of EMT and invadopodia formation, implicating the novel therapeutic potential for AXT in metastatic CRC patients.

Colorectal cancer (CRC) is the third most common cancer, and is associated with a high percentage of cancer-related death globally. Furthermore, the success rate of therapeutic treatment for CRC patients mainly depends on the status of metastasis. Therefore, novel drugs or therapeutic techniques should be discovered for the treatment of metastatic CRC. In this study, we selected Astaxanthin (AXT), one of the most common carotenoids, as a novel metastasis inhibitor through high-throughput drug screening based on invadopodia staining, and confirmed the anti-migratory and anti-invasive activity of AXT. We demonstrated that AXT increases miR-29a-3p and miR-200a expression, and thereby suppresses the expression of MMP2 and ZEB1, respectively. As a result, AXT represses the epithelial-mesenchymal transition (EMT) of CRC cells. Through the mechanistic study, we identified that AXT shows anti-metastatic activity through the transcriptional repression of MYC transcription factor. Finally, we also confirmed that AXT suppresses the in vivo metastatic capacity of colon cancer cell using mouse model. Collectively, we uncovered the novel function of AXT in the inhibition of EMT and invadopodia formation, implicating the novel therapeutic potential for AXT in metastatic CRC patients.

Colorectal cancer (CRC) is the third most common cancer, and is associated with a high percentage of cancer-related death globally. Furthermore, the success rate of therapeutic treatment for CRC patients mainly depends on the status of metastasis. Therefore, novel drugs or therapeutic techniques should be discovered for the treatment of metastatic CRC. In this study, we selected Astaxanthin (AXT), one of the most common carotenoids, as a novel metastasis inhibitor through high-throughput drug screening based on invadopodia staining, and confirmed the anti-migratory and anti-invasive activity of AXT. We demonstrated that AXT increases miR-29a-3p and miR-200a expression, and thereby suppresses the expression of MMP2 and ZEB1, respectively. As a result, AXT represses the epithelial-mesenchymal transition (EMT) of CRC cells. Through the mechanistic study, we identified that AXT shows anti-metastatic activity through the transcriptional repression of MYC transcription factor. Finally, we also confirmed that AXT suppresses the in vivo metastatic capacity of colon cancer cell using mouse model. Collectively, we uncovered the novel function of AXT in the inhibition of EMT and invadopodia formation, implicating the novel therapeutic potential for AXT in metastatic CRC patients.

Colorectal cancer (CRC) is the third most common cancer, and is associated with a high percentage of cancer-related death globally. Furthermore, the success rate of therapeutic treatment for CRC patients mainly depends on the status of metastasis. Therefore, novel drugs or therapeutic techniques should be discovered for the treatment of metastatic CRC. In this study, we selected Astaxanthin (AXT), one of the most common carotenoids, as a novel metastasis inhibitor through high-throughput drug screening based on invadopodia staining, and confirmed the anti-migratory and anti-invasive activity of AXT. We demonstrated that AXT increases miR-29a-3p and miR-200a expression, and thereby suppresses the expression of MMP2 and ZEB1, respectively. As a result, AXT represses the epithelial-mesenchymal transition (EMT) of CRC cells. Through the mechanistic study, we identified that AXT shows anti-metastatic activity through the transcriptional repression of MYC transcription factor. Finally, we also confirmed that AXT suppresses the in vivo metastatic capacity of colon cancer cell using mouse model. Collectively, we uncovered the novel function of AXT in the inhibition of EMT and invadopodia formation, implicating the novel therapeutic potential for AXT in metastatic CRC patients.

Colorectal cancer (CRC) is the third most common cancer, and is associated with a high percentage of cancer-related death globally. Furthermore, the success rate of therapeutic treatment for CRC patients mainly depends on the status of metastasis. Therefore, novel drugs or therapeutic techniques should be discovered for the treatment of metastatic CRC. In this study, we selected Astaxanthin (AXT), one of the most common carotenoids, as a novel metastasis inhibitor through high-throughput drug screening based on invadopodia staining, and confirmed the anti-migratory and anti-invasive activity of AXT. We demonstrated that AXT increases miR-29a-3p and miR-200a expression, and thereby suppresses the expression of MMP2 and ZEB1, respectively. As a result, AXT represses the epithelial-mesenchymal transition (EMT) of CRC cells. Through the mechanistic study, we identified that AXT shows anti-metastatic activity through the transcriptional repression of MYC transcription factor. Finally, we also confirmed that AXT suppresses the in vivo metastatic capacity of colon cancer cell using mouse model. Collectively, we uncovered the novel function of AXT in the inhibition of EMT and invadopodia formation, implicating the novel therapeutic potential for AXT in metastatic CRC patients.
was also confirmed to suppress AOM/DSS-induced colon inflammation and carcinogenesis in animal model through inhibiting the NF-κB pathway. Furthermore, AXT reduces the metastasis of cancer cells by decreasing the expression of MMPs, which are critical for the metastasis of cancer cells through degrading the ECM. Although AXT has been reported to inhibit metastasis in a variety of cancers, the detail mechanisms underlying metastatic potential of CRC remain to be studied.

In this report, we identified AXT as a novel metastasis inhibitor through high-throughput drug screening, and validated the inhibitory effect of AXT on invadopodia formation in colon cancer cells. Furthermore, AXT increases the expression of microRNA-29a-3p (miR-29a-3p) and miR-200a by the transcriptional repression of MYC oncogenic transcriptional factor, thereby abrogating their downstream target genes, MMP2 and ZEB1, and consequently suppressing epithelial-mesenchymal transition (EMT) and metastasis. This study provides the supporting data that AXT inhibits the metastasis of colon cancer through the suppression of invadopodia formation. Collectively, our findings suggest that AXT could have therapeutic activity in metastatic CRC patients.

**Results**

Astaxanthin inhibits invadopodia formation and metastatic capability in colon cancer cells. To identify the novel metastasis inhibitor against CRC, we performed high-throughput drug screening based on invadopodia staining (Fig. S1 of the Supplementary Information (SI)). Among candidates, AXT shows the strongest activity on the reduction of invadopodia formation. To validate whether AXT could potentially suppress invadopodia formation and the consequent suppression of metastasis, metastatic colon cancer cells (CT26 and HCT116) were treated with AXT for 24 h, followed by metastatic analysis through wound and transwell matrigel invasion assays. As shown in Fig. 1A, the abilities of migration and invasion in AXT-treated cells were significantly inhibited, as compared with in DMSO-treated cells. To examine whether AXT inhibits invadopodia formation, CT26 and HCT116 cells were treated with AXT or DMSO, labeled for F-actin and Cortactin as invadopodia marker (Fig. 1B). Furthermore, the activity of matrix degradation by invadopodia was significantly decreased in AXT-treated CT26 and HCT116 cells (Fig. S2 of the SI). Based on MTT assay and in vivo xenograft model, AXT did not show metastasis-suppressing activity by growth inhibition (Fig. S3A–D of the SI).

Because the EMT process is an important step for cancer cells to metastasize, we confirmed whether AXT modulates the EMT in colon cancer cells. Western blotting analysis suggested that the expressions of epithelial marker, E-cadherin were enhanced in AXT-treated HCT116 and CT26 cells (Fig. 1C). In contrast, the mesenchymal marker, Vimentin, was suppressed in AXT-treated cells in a dose-dependent manner. In addition, another invadopodia marker, Cortactin, was also decreased in AXT-treated cells (Fig. 1C). These results showed that AXT is a potential inhibitor of metastasis through the suppression of invadopodia formation and EMT.

Astaxanthin suppresses MMP2 activity through upregulation of miR-29a-3p. Matrix metalloproteinases (MMPs) are enriched in invadopodia, and capable of degrading the ECM and basement membrane (BM) in various tumors by direct targeting MMP2. Numerous studies suggested that expression of MMPs can be used as prognostic markers in colorectal cancer. To confirm the effect of AXT on MMPs expression, HCT116 and CT26 cells were treated with AXT of (30 and 100) μM for 24 h. As shown in Fig. 2A, both mRNA and the protein expression of MMP2 were suppressed in AXT-treated HCT116 and CT26 cells.

Previous studies have reported that miR-29 members suppress cancer angiogenesis, invasion, and metastasis in various tumors by direct targeting MMP2. Therefore, we examined the effect of AXT on miR-29 family expression in colon cancer cells. The expression of miR-29a-3p is significantly upregulated in AXT-treated HCT116 and CT26 cells (Fig. 2B). To further validate whether MMP2 is a direct target of miR-29a-3p, luciferase assay constructs were generated with putative miR-29a-3p binding site in 3’UTR of MMP2 mRNA, including wild type and mutant form (Fig. 2C). As shown in Fig. 2D, miR-29a-3p inhibited the luciferase expression of MMP2 wild type 3’UTR form, but not the mutant one, indicating that miR-29a-3p reduces the MMP2 mRNA stability through direct targeting the 3’UTR of MMP2 mRNA.

To validate the activity of miR-29a-3p on the abrogation of MMP2 by AXT, we generated miR-29a-3p-knockdown colon cancer cells by transfecting miR-29a-3p sponge construct. Inhibition of miR-29a-3p activity caused no significant suppressive effect of AXT on MMP2 mRNA and protein expression compared to control (Fig. 2E). To determine the effect of miR-29a-3p on the metastatic capacity of colon cancer cells, we generated miR-29a-3p overexpressed CT26 cell (Fig. S4A of the SI). Restoration of miR-29a-3p significantly reduced the mRNA and protein level of MMP2 (Fig. S4B of the SI). Furthermore, modulation of miR-29a-3p also markedly reduced the migration and invasion capacities of CT26 cells (Fig. 2F). These results indicate that increased miR-29a-3p by AXT suppresses MMP2 expression by direct targeting 3’UTR of mRNA and influences the migration and invasion activities of colon cancer cells.

Astaxanthin inhibits the expression of ZEB1 through enhancement of miR-200a. ZEB1 is a critical EMT activator in many human cancers, and promotes the metastasis of cancer cells as E-cadherin repressor. As shown in Fig. 3A, ZEB1 mRNA and protein expression were dramatically suppressed in AXT-treated colon cancer cells. Previous studies showed that ZEB1/ZEB2 and miR-200 family negatively regulate each other, which has important implication for EMT and tumor metastasis. To identify the molecular links how AXT modulates ZEB1 expression, we examined whether AXT regulates miRNA-200 family expression, and confirmed that only miR-200a expression was increased by AXT treatment (Fig. 3B).

To validate the effect of miR-200a on the abrogation of ZEB1 by AXT, we generated miR-200a knockdowned colon cancer cells by transfecting miR-200a sponge. Knockdown of miR-200a expression causes no significant suppressive effect of AXT on ZEB1 mRNA and protein expression compared to control (Fig. 3C). To determine the effect of miR-200a on the metastatic capacity of colon cancer cells, we generated miR-200a-overexpressed...
CT26 cell. Overexpression of miR-200a inhibited the mRNA and protein level of ZEB1 in colon cancer cells (Fig. S3 of the SI). In addition, the migration and invasion activity were significantly suppressed in miR-200a overexpressed CT26 cells compared with control cells (Fig. 3D). Taken together, these findings clearly indicate that AXT suppresses ZEB1 by the restoration of miR-200a level, and influences the invasive capability of colon cancer cells.

Astaxanthin negatively regulates MYC oncogenic transcription factor. Previous studies reported that MYC oncogenic transcription factor represses the miR-29 and miR-200 family expression at a transcriptional level by direct interacting with canonical E-box MYC binding sites in promoter region, by which induces cancer metastasis. Based on these studies, we examined whether AXT has inhibitory effect on the expression of MYC transcription factor. As shown in Fig. 4A, MYC protein and mRNA expression level were significantly decreased in AXT-treated colon cancer cells. To verify how AXT regulates MYC expression, we examined Myc promoter activity in AXT-treated CT26 cell. Myc luciferase activity was dramatically suppressed by AXT treatment, suggesting that AXT negatively regulates Myc expression at the transcriptional level (Fig. 4B).

Figure 1. Astaxanthin inhibits the invadopodia formation and metastatic capacity in colon cancer cells. (A) To check the invasive activity of colon cancer cells, wound healing and trans-well matrigel assay were performed with AXT (50 µM) or DMSO-treated colon cancer cells. Images were captured with microscopy 24 h after treatment of AXT or DMSO. The migrated and invaded cells were quantified with Image J software to compare with control. (B) To evaluate the invadopodia formation, colon cancer cells were treated with AXT or DMSO with the indicated concentrations for 24 h. Cells were fixed and labeled for F-actin (red) and Cortactin (green) as invadopodia markers. Scale bar, 50 μm. Staining intensity was compared with Image J program from at least three fields. (C) Invadopodia (Cortactin) and EMT markers (E-cadherin and Vimentin) were detected in AXT-treated colon cancer cells with specific antibodies. The β-actin band was validated as normalization control. Expression level of specific protein was measured with densitometry, and presented as relative density. Values are mean ± SD from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
Next, we verified the negative correlation between MYC and miR-29a-3p/miR-200 expression. The miR-29a-3p and miR-200a expression was measured in Myc knockdowned HCT116 cell by qRT-PCR (Fig. 4C). The expression of anti-metastatic miRs (miR-29a-3p and miR-200a) was recovered in Myc knockdowned cell. The knockdown efficacy of Myc was confirmed by western blot. More specifically, knockdown of Myc increases the miR-200a expression at the transcriptional level (Fig. 4D). Overall, these results suggest that AXT inhibits Myc expression at the transcription level, thereby restoring miR-29a-3p and miR-200a expression, and suppresses the metastatic ability of colon cancer cells.

Astaxanthin suppresses the metastatic activity of colon cancer cell in in vivo model. To determine whether AXT suppresses in vivo tumor metastasis, we injected CT26 cell (1 × 10^6) through the tail vein. The mice were randomly separated into three groups and treated with AXT (25 or 50 mg/kg) every day. The non-treated group developed lung metastasis rapidly in nude mice, whereas the metastatic growth of CT26 in lungs was completely suppressed in AXT-treated groups (Fig. 5A). Such difference was confirmed with whole-lung visualization by hematoxylin and eosin (H&E) staining of lung sections (Fig. 5B). Immunohistochemical analysis of MYC, Cortactin, and ZEB1 also showed AXT suppresses metastasis of colon cancer cells into lung (Fig. 5C). Finally, we checked the expression level of MMP2 in tumor tissues by western blot analysis. The expression of MMP2 was highly expressed in the non-treated group, but was decreased in the AXT-treated groups (Fig. 5D).

Figure 2. Astaxanthin suppresses the expression of MMP2 through upregulation of the miR-29a-3p. (A) To check the effect of AXT on MMP2 expression, cells were treated with AXT at the indicated doses. After isolating RNA and protein, expression of MMP2 was detected with qRT-PCR and western blot in AXT-treated colon cancer cells to compare with control cell. (B) To determine the expression level of miR-29a-3p in AXT-treated colon cancer cells, total RNA was purified, and examined with miRNA-specific qRT-PCR. Level of 18S RNA was detected as housekeeping control. (C) Schematic showing the miRNA binding sequence in the 3′UTR of MMP2 gene, which is targeted bymiR-29a-3p. The 3′UTR region of MMP2 was amplified, and cloned into the pmIR-REPORT luciferase reporter construct. Mutant having nucleotide changes at miR-29a-binding sites was generated as indicated. (D) Luciferase reporter activity was measured with pmIR-REPORT construct including wild type or mutant MMP2 3′UTR into miR-29a-3p-overexpressed CT26 cell. Incubated cells were collected to compare the relative luciferase activity. The raw data were normalized with β-galactosidase activity. (E) To confirm the effect of miR-29a-3p on MMP2 suppression by AXT, miR-29a-3p expression was suppressed by transfecting with miR-29a-3p sponge. The expression of MMP2 mRNA and protein was determined via qRT-PCR and western blot. The Cyclophilin gene and β-actin were used as loading control, respectively. (F) Wound assay and invasion assay were performed with miR-29a-overexpressing CT26 cells. The percentage of wound closure or invaded cells was compared with non-treated cell. *P < 0.05; **P < 0.01; ***P < 0.001.
Taken together, our results revealed that AXT suppresses the metastasis of colon cancer cell through the inhibition of invadopodia formation and EMT process.

Discussion
Although many studies show that AXT is an interesting anti-cancer therapeutics through the modulation of multiple hallmarks of cancer, including proliferation, apoptosis, necrosis, autophagy, oxidation, and invasion, a little information is available on the function of AXT in colon cancer. It has been reported that AXT suppresses cancer development targeting the JAK/STAT3 pathway and its downstream target gene expression of MMPs in a hamster model of oral cancer. AXT was also found to suppress invasion in colon cancer by inhibiting the expression of MMPs, NF-κB, and Erk. Furthermore, AXT reduces the activity of MMPs to suppress the metastasis of melanoma cancer cell in an in vitro and in vivo model. Although we presented the anti-metastatic activity of AXT with single treatment, it will be interesting to check the efficiency for combinatorial treatment with a wide range of chemotherapeutics to achieve better outcomes.

In this study, we report the anti-metastatic activity of AXT based on the suppression of invadopodia formation, EMT, consequent actin polymerization, matrix degradation, and the in vivo metastatic capacity of colon cancer cells. More specifically, we demonstrated that AXT restored the expression of miR-29a-3p and miR-200a by the inhibition of MYC oncogenic transcription factor. Through double-negative regulation, increased miRNAs suppress the expression of MMP2 and ZEB1 by direct targeting (Fig. 5E). We have identified several microRNAs (miRNAs) to elucidate the molecular link how AXT inhibits cancer cell metastasis by repressing MMP2 and ZEB1 expression. Previous report indicated that miR-29 family suppresses cancer angiogenesis, invasion, and metastasis in various tumors, through directly targeting the MMP expression. Bracken et al. reported that ZEB1 is an important and strong regulator of EMT and tumor metastasis, by which a double-negative feedback loop is established between ZEB1/2 and the miR-200 family. On the basis of these results, we validated several putative miRNAs to find the target miRNAs that AXT regulates the expression of. Intriguingly, miR-29a-3p and miR-200a expression was increased in AXT-treated colon cancer cells in a dose-dependent manner.

The oncogenic Myc gene is upregulated in various human cancers, and can promote or suppress the transcription of carcinogenesis-associated genes. MYC also showed a marked effect on miRNA expression, which is widely

![Figure 3. Astaxanthin inhibits the expression of ZEB1 through the enhancement of miR-200a. (A) To examine the effect of AXT on ZEB1 expression, cells were treated with AXT at the indicated doses. After isolating RNA and protein, expression of ZEB1 was detected with qRT-PCR and western blot and compared with control cell. (B) To determine the expression level of miR-200a in AXT-treated colon cancer cells, total RNA was isolated and examined with miRNA-specific qRT-PCR. Level of 18S RNA was detected for normalization. (C) To evaluate the inhibitory effect of miR-200a on ZEB1 by AXT, miR-200a expression was reduced by treating with miR-200a sponge. The expression level of ZEB1 mRNA and protein was determined by qRT-PCR and western blot. The Cyclophilin gene and β-actin were used as loading control, respectively. (D) Wound closure and invasion assay were performed with miR-200a-overexpressing CT26 cell. The percentage of wound closure or invaded cells was compared with non-treated cell. *P < 0.05; **P < 0.01; ***P < 0.001.]
downregulated, except with a miR-17–92 cluster, which is upregulated. Much evidence demonstrated that several miRNAs are downregulated by MYC suggesting that miRNAs act as tumor suppressor. For example, RAS targeting let-7 miRNA shows low expression in lung cancer. The miR-34a having anti-carcinogenic activity is also suppressed by MYC. Furthermore, MYC downregulates the miR-29 family to enhance the expression of AKT2 and CCND2, which is involved in AML development. Previous reports demonstrated that MYC negatively regulated the miR-29 and miR-200 family through direct interaction on canonical E-boxes MYC binding sites in miR-29 (5’ CACGTG located at −261 and 5’ CACATG; −1317 from the transcription start site) and miR-200 (−110/+19) promoter region which resulted in elevated EMT. Based on the above results, we confirmed whether MYC transcription factor suppresses miR-29a-3p and miR-200a expression. As a result, the expression of miR-29a-3p and miR-200a expression was increased in Myc knockdowned colon cancer cell, and AXT suppresses Myc expression at the transcriptional level. These results suggest that the increase in expression of miR-29a-3p and miR-200a by AXT occurs through suppression of the MYC transcription factor. Although many studies reported that AXT suppresses the expression of NF-κB and STAT3, transcription factors of MYC, to abrogate carcinogenesis in various cancer cells, the detail regulatory mechanisms are still elucidated. Previous study has shown that master regulator of EMT process, Twist1 induces invadopodia formation through activating PDGF-Rs expression. The authors also mentioned that activation of Twist1 and invadopodia formation are required to degrade the basement membrane in vivo. Like Twist1, MYC also positively regulated the EMT process, and was suppressed by AXT. Figure 3 shows the regulatory mechanism of MYC and Twist1 in EMT process.
function as anti-metastasis inhibitor through multiple mechanisms. Because AXT is a multi-functional carotenoid that is involved in various biological processes, many unidentified targets can be tested. To confirm the value of AXT as anti-metastasis drug, further studies are required to elucidate whether AXT modulates other specific target genes in the process of metastasis.

Invadopodia are actin-polymerized cell membrane adhesive structures to escape the basement membrane formed by metastasizing cancer cells. Therefore, ECM destruction is a critical process to initiating cancer invasion and metastasis. Based on previous observations regarding the ability of invadopodia to extravasate the cancer cells through endothelial layer, we hypothesized that invadopodia inhibition could prevent the extravasation of cancer cells and subsequent tumor development. When we performed high-throughput drug screening based on invadopodia staining, it successfully identified the potential metastasis inhibitor (Fig. S1 of the SI). Therefore, it would be a valuable approach to screen more chemical libraries or natural compounds, to select novel therapeutics.

Methods
Antibodies and reagents. Synthetic AXT was purchased from Sigma-Aldrich, and dissolved in dimethyl sulfoxide (DMSO) to yield a 100 mM stock solution, and stored at –20 °C for future use. The primary antibodies (anti-E-cadherin (24E10), anti-Vimentin (5741) and anti-MMP2 (D204T)) were obtained from Cell Signaling. Anti-MYC (9E10) and anti-Cortactin (H-191) were obtained from Santa Cruz. Anti-β-actin (A5441) antibody was a product of Sigma Aldrich. Rhodamine Phalloidin (Thermo Fisher) was used for F-actin staining.
Cell Lines and Culture. The human colon cancer cell HCT116 was cultured in RPMI-1640 (WelGENE, Korea), supplemented with 10% FBS, 1% penicillin, and streptomycin. Mouse colon cancer cell CT26 (ATCC) was cultured in DMEM (WelGENE) with 10% FBS, 1% penicillin, and streptomycin. Colon cancer cell lines were incubated at 37 °C in a 5% CO₂ incubator.

High-throughput screening for metastasis inhibitor. Colon cancer cells were plated onto 96-well chamber slides with 5,000 cells/well (Nunc™ Lab-Tek™ II Chamber Slide™). After 24 h, LOPAC1280 library (Sigma Aldrich) compound was treated with final concentration of 10 μM for a further 16 h. Cells were treated with Src family kinase inhibitor (SU6656) as positive control, or with vehicle (0.5% DMSO) as negative control. To verify the invadopodia structure, cells were fixed with fixation solution (3.7% PFA) for 15 min. Wells were aspirated and washed with PBS, then incubated with 0.1% Triton X-100 for 15 min. Cells were incubated with 5% BSA for 30 min, and stained with F-actin-phalloidin (1:500, Invitrogen) for overnight at 4 °C and DAPI (1:10,000) for 1 min. Images of invadopodia structure were taken and compared with Image J software (NIH) from at least three fields.

qRT–PCR. To measure the expression level of specific genes, RNA was isolated from colon cancer cells with TRizol reagent (Invitrogen). Table S1 of the SI shows the specific primers. Reverse-transcribed RNA with SuperScript II (Invitrogen) was analyzed with qRT-PCR using Prism 7900HT sequence detection system (Applied Biosystem) and SYBR-green Premix Ex-Tag II (Takara). Raw data were analyzed with comparative Ct method using Cyclophilin gene as normalization control. Expression of miRNA was checked with TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems), following the manufacturer’s method. Level of 18S RNA was measured for the normalization of miRNAs. Data were analyzed in at least triplicate, and expressed as mean ± S.D.

Cell viability assay. The colon cell cancer lines (HCT116 and CT26) were plated onto 96-well plates (2 × 10⁴ cells/ml) and incubated for 24 h. Then, media were replaced with 100 μl of media containing indicated concentrations of AXT of (50, 100) μM for another 24 h. Then, cell viability was measured using the CCK8 and microplate reader at a wavelength of 450 nm.

Western blot analysis. Protein lysates were extracted with a solubilization buffer (25 mM HEPES (pH 7.5), 1% Triton X-100, 5 mM EDTA, 10% glycerol, 150 mM NaCl, and a protease inhibitor cocktail) for 30 min and debris were removed with high-speed centrifugation at 10,000 × g for 10 min at 4 °C. For detecting target protein, protein samples were separated by SDS–polyacrylamide gel electrophoresis. Then, protein were detected with specific antibodies and visualized with chemiluminescence reagents according to the manufacturer’s method (Pierce).

Generation of overexpression or knockdown colon cancer cell lines. To make the miR-29a-3p and miR-200a expression construct, the pCDH-CMV-MCS-EF1-copGFP (System Biosciences) system was used for cloning of miR-29a-3p and miR-200a DNA. Table S2 of the SI shows the sequences of each microRNA. After cloning of miR-200a expression construct, the pCDH-CMV-MCS-EF1-copGFP (System Biosciences) and SYBR-green Premix Ex-Tag II (Takara). Raw data were analyzed with comparative Ct method using Cyclophilin gene as normalization control. Expression of miRNA was checked with TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems), following the manufacturer’s method. Level of 18S RNA was measured for the normalization of miRNAs. Data were analyzed in at least triplicate, and expressed as mean ± S.D.

Luciferase reporter assay. The potential miR-29a-3p interaction site of MMP2 gene was inserted into the pMIR-REPORT™ vector. For mutant form, the miR-29a-3p binding site of MMP2 (GGTGGCT) was replaced with mutant sequences (AGGAGCT) via site-directed mutagenesis. For Myc promoter assay, Myc promoter region was cloned into pGL3b vector. CT26 cells were cotransfected with the pGL3b-Myc reporter plasmid along with mutant sequences (GGTGGCT) via site-directed mutagenesis. For Myc promoter assay, Myc promoter region was cloned into pGL3b vector. CT26 cells were cotransfected with the pGL3b-Myc reporter plasmid along with mutant sequences (GGTGGCT) via site-directed mutagenesis. For Myc promoter assay, Myc promoter region was cloned into pGL3b vector. CT26 cells were cotransfected with the pGL3b-Myc reporter plasmid along with mutant sequences (GGTGGCT) via site-directed mutagenesis. For Myc promoter assay, Myc promoter region was cloned into pGL3b vector. CT26 cells were cotransfected with the pGL3b-Myc reporter plasmid along with mutant sequences (GGTGGCT) via site-directed mutagenesis. For Myc promoter assay, Myc promoter region was cloned into pGL3b vector. CT26 cells were cotransfected with the pGL3b-Myc reporter plasmid along with mutant sequences (GGTGGCT) via site-directed mutagenesis.
**In vivo metastasis analysis.** BALB/c nu/nu mice (6 weeks old, 16–18 g, Orient Bio, Korea) were housed based on Institutional Animal Care and Use Committee-approved protocols of Gachon University. All animal experiments were performed in accordance with relevant guidelines and regulations. Mouse colon cancer CT26 cells (1 x 10^6) were injected intravenously into the tail veins of mice. The through tail veins of nude mice. The experimental groups received daily intraperitoneal injections of AXT of (25 or 50 mg/kg). After 4 weeks injection, lung tissues were collected to check the metastasized colon cancer cells and perform the further analysis.

**Statistical analysis.** All statistics analyzed with GraphPad Prism 5 program. Data are represented into mean ± S.D of three independent results. Analysis between different groups were performed with a 2-tailed paired Student's t-test. Data were marked as statistically significant if the P value was < 0.05.

**References**

1. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA: a cancer journal for clinicians 55, 74–108 (2005).
2. Rihimaki, M., Thomsen, H., Sundquist, K. & Hemminki, K. Colorectal cancer patients: what do they die of? Frontline gastroenterology 3, 143–149, https://doi.org/10.1136/flgastro-2012-100141 (2012).
3. van der Geest, L. G. et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clinical & experimental metastasis 32, 457–465, https://doi.org/10.1007/s12019-015-9719-0 (2015).
4. Fidler, I. J. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature reviews cancer 3, 453–458, https://doi.org/10.1038/nrc1098 (2003).
5. Weidner, N., Semple, J. P., Welch, W. R. & Folkman, J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. The New England journal of medicine 324, 1–8, https://doi.org/10.1056/nejm199101303240101 (1991).
6. Weaver, A. M. Invadopodia: specialized cell structures for cancer invasion. Clinical & experimental metastasis 23, 97–105, https://doi.org/10.1007/s12019-006-9041-4 (2006).
7. Buccione, R., Caldieri, G. & Ayala, I. Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer metastasis reviews 28, 137–149, https://doi.org/10.1007/s10555-008-9176-1 (2009).
8. Monsky, W. L. et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer research 54, 5702–5710 (1994).
9. Eckert, M. A. et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer cell 19, 372–386, https://doi.org/10.1016/j.ccr.2011.01.036 (2011).
10. Gligorijevic, B. et al. N-WASP-mediated invadopodium formation is involved in invasation and lung metastasis of mammary tumors. Journal of cell science 125, 724–734, https://doi.org/10.1242/jcs.092726 (2012).
11. Gil-Henn, H. et al. Arg/A2b2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene 32, 2622–2630, https://doi.org/10.1038/onc.2012.284 (2013).
12. Kidd, P. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review: a journal of clinical therapeutic 16, 355–364 (2011).
13. Guerin, M., Huntley, M. E. & Olaizola, M. Haematococcus astaxanthin: applications for human health and nutrition. Trends in biotechnology 21, 210–216, https://doi.org/10.1016/S0167-7799(01)01817-2 (2003).
14. Kavitha, K., Kowshik, J., Kishore, T. K., Baba, A. B. & Nagini, S. Astaxanthin inhibits NF-κB and Wnt/beta-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochimica et biophysica acta 1830, 4433–4444, https://doi.org/10.1016/j.bbagen.2013.05.032 (2013).
15. Yasui, Y., Hosokawa, M., Mikami, N., Miyashita, K. & Tanaka, T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chemico-biological interactions 193, 79–87, https://doi.org/10.1016/j.cbiores.2011.05.006 (2011).
16. Nagendraprabhu, P. & Sudhandiran, G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFKβ and COX-2. Investigational new drugs 29, 207–224, https://doi.org/10.1007/s10635-009-9342-5 (2011).
17. Kosuki, Y., Miura, Y. & Yagasaki, K. Inhibitory effects of carotenoids on the invasion of rat ascts hepatoma cells in culture. Cancer letters 151, 111–115 (2000).
18. Matrisian, L. M. Metalloproteinases and their inhibitors in matrix remodeling. Trends in biotechnology 20, 28–34, https://doi.org/10.1016/S0167-7799(01)01813-X (2002).
19. Baker, E. A. & Leaper, D. J. Measuring gelatinase activity in colorectal cancer. European journal of surgical oncology 24, 24–29, https://doi.org/10.1053/ejos.2001.1179 (2002).
20. D’Errico, A. et al. Augmentation of type IV collagenase, laminin receptor, and K677 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Modern pathology 4, 239–246 (1991).
21. D’Errico, A. et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 54, 1729–1740, https://doi.org/10.1002/hep.24577 (2011).
22. Wang, H. et al. miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin beta1 and matriloxoproteinase2 (MMP2). PLoS one 8, e70192, https://doi.org/10.1371/journal.pone.0070192 (2013).
23. Therri, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890, https://doi.org/10.1016/j.cell.2009.11.007 (2009).
24. Nieto, M. A. & Cano, A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Seminars in cancer biology 22, 361–368, https://doi.org/10.1016/j.semcancer.2012.05.003 (2012).
25. Bracken, C. P. et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer research 68, 7846–7854, https://doi.org/10.1158/0008-5472 can-08-1942 (2008).
26. Burk, U. et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO reports 9, 582–589, https://doi.org/10.1038/embor.2008.74 (2008).
27. Mott, J. L. et al. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. Journal of cellular biochemistry 110, 1155–1164, https://doi.org/10.1002/jcb.22630 (2010).
28. Wu, D. W. et al. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene 34, 2072–2082, https://doi.org/10.1038/onc.2014.152 (2015).
29. Bai, J. X. et al. Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines. Endocrinology 154, 635–645, https://doi.org/10.1210/en.2012-1607 (2013).
30. Kowshik, J. et al. Astaxanthin inhibits AKT/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. PLoS one 9, e91914, https://doi.org/10.1371/journal.pone.019114 (2014).
31. Kang, M. R. et al. NF-kappaB signalling proteins p50/p105, p52/p100, RelA, and IKKpseud are over-expressed in oesophageal squamous cell carcinomas. Pathology 41, 622–625, https://doi.org/10.3109/03009325093257755 (2009).
33. O’Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V. & Mendell, J. T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839–843, https://doi.org/10.1038/nature03677 (2005).
34. Calin, G. A. et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. The New England journal of medicine 353, 1793–1801, https://doi.org/10.1056/NEJMoa050995 (2005).
35. Calin, G. A. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America 101, 2999–3004, https://doi.org/10.1073/pnas.0307333101 (2004).
36. Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635–647, https://doi.org/10.1016/j.cell.2005.01.014 (2005).
37. Chang, T. C. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular cell 26, 745–752, https://doi.org/10.1016/j.molcel.2007.05.010 (2007).
38. Gong, I. N. et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell death and differentiation 21, 100–112, https://doi.org/10.1038/cdd.2013.133 (2014).
39. Song, X. et al. Changes in cell ultrastructure and inhibition of JAK1/STAT3 signaling pathway in CBRH-7919 cells with astaxanthin. Toxicology mechanisms and methods 22, 679–686, https://doi.org/10.3109/15376516.2012.717119 (2012).
40. Tarone, G., Cirillo, D., Giancotti, F. G., Comoglio, P. M. & Marchisio, P. C. Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Experimental cell research 159, 141–157 (1985).
41. Chen, W. T. Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. The Journal of experimental zoology 251, 167–185, https://doi.org/10.1002/jez.1402510206 (1989).

Acknowledgements
This study was supported by the National Research Foundation of Korea (NRF) grant (2016R1A2B2008007) to S.H., and by Basic Science Research Program grant (2016R1D1A1B03930491) to H.Y.K. funded by the Korea government.

Author Contributions
H.Y.K. and Y.M.K. performed the experiments, analyzed and interpreted the data. H.Y.K. and S.H. designed the study and wrote the manuscript. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-45924-3.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019